Drug Discovery World

DECEMBER 22, 2023

Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. We now look forward to the next stage of clinical development.” The post Positive Phase I results for solid dose prescription CBD medicine appeared first on Drug Discovery World (DDW).

Medicine 52

Medicine Bioavailability Clinical Development Trials 52

Pharmaceutical Technology

AUGUST 30, 2022

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

Development 130

Development Drugs Bioavailability Production 130

XTalks

MAY 23, 2024

Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. These include broad-spectrum sunscreens, protective clothing and innovative skincare products developed using antioxidants and other protective agents.

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

pharmaphorum

NOVEMBER 9, 2022

for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Development 40

Development Bioavailability Production Medicine 40

XTalks

APRIL 11, 2023

Most people typically develop Parkinson’s disease after the age of 60, and early onset forms of Parkinson’s disease are often inherited, though some forms may be linked to genetic mutations or exposure to environmental toxins like pesticides. Ambroxol is a cough medicine in the mucolytics family (thins and removes mucus from airways).

Bioavailability 98

Bioavailability Genetics Nurses Development 98

The Pharma Data

MARCH 8, 2021

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Development of molnupiravir is entirely funded by Ridgeback Biotherapeutics and Merck & Co.,

Trials 69

Trials In-Vivo Genotoxicity RNA 69